BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//TYPO3/NONSGML News system (news)//EN
BEGIN:VEVENT
UID:news-12346@inano.au.dk
DTSTAMP:20250918T085803Z
DTSTART:20250926T081500Z
DTEND:20250926T090000Z
END:VEVENT
END:VCALENDAR




<div class="news news-single">
	<div class="article" itemscope="itemscope" itemtype="http://schema.org/Article">
		
	
			<script type="text/javascript">
				const showAllContentLangToken = "Show all content ";
			</script>

			
			

			<article class="typo3-delphinus delphinus-gutters">

				<!-- News PID: 4816 - used for finding folder/page which contains the news / event -->
				<!-- News UID: 12346 - the ID of the current news / event-->

				<div class="news-event">
					<div class="news-event__header">
						<!-- Categories -->
						
							<span class="text--stamp">
<!-- categories -->
<span class="news-list-category">
	
		
	
</span>

</span>
						

						<!-- Title -->
						<h1 itemprop="headline">Distinguished Lecture by Prof. Luis Álvarez-Vallina, H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO)</h1>
						
							<!-- Teaser -->
							<p class="text--intro" itemprop="description">Next-generation adoptive cell therapies for cancer</p>
						
					</div>

					
						<!-- Top image -->
						
					

					<div class="news-event__content">

						<!-- Events info box -->
						
								

								<div class="news-event__info theme--dark" id="event-info">
									<h2 class="screenreader-only">Info about event</h2>

									
											<!--- Same date -->
											<div class="news-event__info__item news-event__info__item--time">
												<h3 class="news-event__info__item__header text--label-header">Time</h3>
												<div class="news-event__info__item__content">
													<span class="u-avoid-wrap">
														Friday 26  September 2025,
													</span>
													<span class="u-avoid-wrap">
														&nbsp;at 10:15 -  11:00
													</span>
													<p class="news-event__info__item__ical-link"><a href="/about/news-events/news/show/artikel/distinguished-lecture-by-prof-luis-alvarez-vallina-h12o-cnio-cancer-immunotherapy-clinical-research-unit-spanish-national-cancer-research-centre-cnio?tx_news_pi1%5Bformat%5D=ical&amp;type=9819&amp;cHash=92d72b07894b6bbbb5e2fb9a3a032a56">Add to calendar</a></p>
												</div>
											</div>
										

									<!-- Location detailed -->
									
											<div class="news-event__info__item">
												<h3 class="news-event__info__item__header text--label-header">Location</h3>
												<div class="news-event__info__item__content">
													<p>iNANO Auditorium (1593-012)</p>
													
												</div>
											</div>
										

									<!-- Organizer detailed -->
									
											<!-- Organizer Simple -->
											
												<div class="news-event__info__item">
													<h3 class="news-event__info__item__header text--label-header">Organizer</h3>
													<div class="news-event__info__item__content">
														Associate Professor Ken Howard
													</div>
												</div>
											
										

									<!-- Price -->
									

									<!-- Event link -->
									

									<!-- Registration -->
									
								</div>
							

						
							<!-- Media -->
							
								



							
						

						
							<div class="news-event__content__text">
								<span class="text--byline" id="byline">
									

									<!-- Author -->
									
										<span itemprop="author" itemscope="itemscope" itemtype="http://schema.org/Person">
											
													By
												

											
													<a href="mailto:Helpers@inano.au.dk">
														<span itemprop="name">Lea Thamdrup Habicht</span>
													</a>
												
										</span>
									
								</span>

								

									<!-- Body text -->
									<h2><a href="https://www.cnio.es/en/personas/luis-manuel-alvarez-2/" target="_self">Professor Luis Álvarez-Vallina, Spanish National Cancer Research Centre (CNIO)</a></h2>
<p>Host: Accosiate Prof. Ken Howard</p>
<h3><strong><em>Next-generation adoptive cell therapies for cancer</em></strong></h3>
<p>T lymphocyte redirection has been addressed by two main approaches: systemic infusion of bispecific T cell engagers (TCEs), which simultaneously bind CD3 and a tumor-associated antigen (TAA), and adoptive transfer of genetically modified T cells expressing TAA-specific chimeric antigen receptors (CARs). We have developed a novel strategy based on in situ secretion of TCE antibodies by engineered T cells, termed <strong>STAb-T cells</strong>, which combines the active trafficking of adoptively transferred T cells to the tumor with polyclonal T cell recruitment by locally secreted TCEs. This approach integrates the strengths of CAR-T and TCEs, while potentially mitigating some of their limitations. Adoptive transfer of STAb-T cells has demonstrated potent antitumor activity in preclinical models of both solid and hematological malignancies. Importantly, this innovative platform is now approaching clinical translation, with the first-in-human trial of CD19-STAb expected to start soon, marking a new step in the evolution of adoptive cell therapies for cancer.</p>
								
							</div>
						
					</div>

					
						<!-- Content elements -->
						
					
				</div>
			</article>

			
				
				
			

			<!-- related things -->
			
		

	</div>
</div>